Cardiometabolic & kidneyRandomised controlled trial
Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial
- Randomised controlled trial
- double-blind
- placebo-controlled
Authors' conclusion
This study suggests that low-dose colchicine may reduce arterial stiffness in high risk patients with type 2 diabetes.
Study context
- Population
- T2DM with a history of cardiovascular disease (CVD) or high CV risk1:1 randomisation
- Participants
- 100 participants
- Comparison
- Colchicine vs placebo
- Primary endpoint
- Change in arterial stiffness (carotid-femoral pulse wave velocity, cfPWV)
- Follow-up
- 26 weeks
Primary result
Change in arterial stiffness (cfPWV)
Mean arterial pressure (MAP)-adjusted change in carotid-femoral pulse wave velocity (cfPWV)
−0.7 m/s
95% CI −1.3 to −0.1
P = 0.03
Colchicine vs Placebo
MAP-adjusted change in cfPWV −0.7 m/s (95% CI −1.3 to −0.1); P = 0.03
As reported in the abstract
- Crude analysis without MAP adjustment: non-significant reduction in cfPWV
- −0.3 m/s (95% CI: −1.0; 0.4, P = 0.45)
Secondary outcomes
| Outcome | change (mmHg) (95% CI) | P value | |
|---|---|---|---|
| 24-h systolic ambulatory BP · no significant effect | 3.0 (−0.5 to 6.5) | P = 0.10 | |
| −50510Difference, mmHg (linear scale) |
| Outcome | percentage change (95% CI) | P value | |
|---|---|---|---|
| UACR · no significant effect | 0.5 (−29.5 to 40.4) | P = 0.98 | |
| −40−200204060Difference (linear scale) |
Original publication
Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial. Eur J Prev Cardiol. Published 14 March 2025. doi:10.1093/eurjpc/zwaf143
Summarised from the published abstract; every number is checked against it